148 related articles for article (PubMed ID: 31389383)
1. A prospective, randomized study to compare the combination of imatinib and cytarabine versus imatinib alone in newly diagnosed patients with chronic phase chronic myeloid leukemia.
Samal P; Chakrabarti P; Nath UK
Indian J Cancer; 2019; 56(3):211-215. PubMed ID: 31389383
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
[TBL] [Abstract][Full Text] [Related]
3. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
Gardembas M; Rousselot P; Tulliez M; Vigier M; Buzyn A; Rigal-Huguet F; Legros L; Michallet M; Berthou C; Cheron N; Maloisel F; Mahon FX; Facon T; Berthaud P; Guilhot J; Guilhot F;
Blood; 2003 Dec; 102(13):4298-305. PubMed ID: 12933584
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
[TBL] [Abstract][Full Text] [Related]
5. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Preudhomme C; Guilhot J; Nicolini FE; Guerci-Bresler A; Rigal-Huguet F; Maloisel F; Coiteux V; Gardembas M; Berthou C; Vekhoff A; Rea D; Jourdan E; Allard C; Delmer A; Rousselot P; Legros L; Berger M; Corm S; Etienne G; Roche-Lestienne C; Eclache V; Mahon FX; Guilhot F; ;
N Engl J Med; 2010 Dec; 363(26):2511-21. PubMed ID: 21175313
[TBL] [Abstract][Full Text] [Related]
6. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
O'Brien SG; Guilhot F; Larson RA; Gathmann I; Baccarani M; Cervantes F; Cornelissen JJ; Fischer T; Hochhaus A; Hughes T; Lechner K; Nielsen JL; Rousselot P; Reiffers J; Saglio G; Shepherd J; Simonsson B; Gratwohl A; Goldman JM; Kantarjian H; Taylor K; Verhoef G; Bolton AE; Capdeville R; Druker BJ;
N Engl J Med; 2003 Mar; 348(11):994-1004. PubMed ID: 12637609
[TBL] [Abstract][Full Text] [Related]
7. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Thielen N; van der Holt B; Verhoef GE; Ammerlaan RA; Sonneveld P; Janssen JJ; Deenik W; Falkenburg JH; Kersten MJ; Sinnige HA; Schipperus M; Schattenberg A; van Marwijk Kooy R; Smit WM; Chu IW; Valk PJ; Ossenkoppele GJ; Cornelissen JJ
Ann Hematol; 2013 Aug; 92(8):1049-56. PubMed ID: 23572137
[TBL] [Abstract][Full Text] [Related]
8. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Smith TL; Cortes J; Giles FJ; Rios MB; Mallard S; Gajewski J; Murgo A; Cheson B; O'Brien S
J Clin Oncol; 2000 Oct; 18(20):3513-21. PubMed ID: 11032593
[TBL] [Abstract][Full Text] [Related]
9. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
10. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
Cervantes F; López-Garrido P; Montero MI; Jonte F; Martínez J; Hernández-Boluda JC; Calbacho M; Sureda A; Pérez-Rus G; Nieto JB; Pérez-López C; Román-Gómez J; González M; Pereira A; Colomer D
Haematologica; 2010 Aug; 95(8):1317-24. PubMed ID: 20220063
[TBL] [Abstract][Full Text] [Related]
11. [Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia].
Zhou L; Wang JX; Huang XJ; Hu JD; Shen ZX
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):93-7. PubMed ID: 23611212
[TBL] [Abstract][Full Text] [Related]
12. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
Kwak JY; Kim SH; Oh SJ; Zang DY; Kim H; Kim JA; Do YR; Kim HJ; Park JS; Choi CW; Lee WS; Mun YC; Kong JH; Chung JS; Shin HJ; Kim DY; Park J; Jung CW; Bunworasate U; Comia NS; Jootar S; Reksodiputro AH; Caguioa PB; Lee SE; Kim DW
Clin Cancer Res; 2017 Dec; 23(23):7180-7188. PubMed ID: 28939746
[No Abstract] [Full Text] [Related]
13. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
[TBL] [Abstract][Full Text] [Related]
14. [A study to determine the safety and efficacy of imatinib mesylate in patients with chronic phase of chronic myeloid leukemia after interferon therapy failure. Four year follow-up].
Hołowiecki J; Konopka L; Bober G; Giebel S; Ceglarek B; Kos K; Stella-Hołowiecka B; Kruzel T; Kopera M; Bartkowska-Chrobok A; Pszenna E; Sikorska A; Pieńikowska-Grela B
Pol Arch Med Wewn; 2006 Jun; 115(6):535-44. PubMed ID: 17263225
[TBL] [Abstract][Full Text] [Related]
15. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
[TBL] [Abstract][Full Text] [Related]
16. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
17. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.
Sohn SK; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Yoon SS; Kim H; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Moon JH; Park SY
Leuk Lymphoma; 2011 Jun; 52(6):1024-9. PubMed ID: 21463107
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India.
Phukan A; Mandal PK; Dolai TK
Ann Hematol; 2021 Jan; 100(1):85-96. PubMed ID: 33025163
[TBL] [Abstract][Full Text] [Related]
19. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.
Maloisel F; Guerci A; Guyotat D; Ifrah N; Michallet M; Reiffers J; Tertain G; Blanc M; Bauduer F; Brière J; Abgrall JF; Pegourie-Bandelier B; Solary E; Cambier N; Coso D; Vilque JP; Delain M; Harousseau JL; Rousselot P; Belhadj K; Morice P; Attal J; Chabin M; Chastang C; Guilhot J; Guilhot F;
Leukemia; 2002 Apr; 16(4):573-80. PubMed ID: 11960335
[TBL] [Abstract][Full Text] [Related]
20. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
Silver RT; Peterson BL; Szatrowski TP; Powell BL; Stock W; Carroll AJ; Bloomfield CD; Schiffer CA; Larson RA
Leuk Lymphoma; 2003 Jan; 44(1):39-48. PubMed ID: 12691141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
